Check for updates

#### **OPEN ACCESS**

EDITED BY Lingling Wei, Capital Medical University, China

REVIEWED BY Hongxing Fu, Zhejiang University, China Adriana Migliorini, University Health Network, Canada Zhongqiang Zhang, Central South University, China

\*CORRESPONDENCE Lisha Mou Kishamou@email.szu.edu.cn

<sup>†</sup>These authors have contributed equally to this work

RECEIVED 26 March 2024 ACCEPTED 02 August 2024 PUBLISHED 29 August 2024

#### CITATION

Pu Z, Chen S, Lu Y, Wu Z, Cai Z and Mou L (2024) Exploring the molecular mechanisms of macrophages in islet transplantation using single-cell analysis. *Front. Immunol.* 15:1407118. doi: 10.3389/fimmu.2024.1407118

#### COPYRIGHT

© 2024 Pu, Chen, Lu, Wu, Cai and Mou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

## Exploring the molecular mechanisms of macrophages in islet transplantation using single-cell analysis

Zuhui Pu<sup>1,2†</sup>, Shujuan Chen<sup>3†</sup>, Ying Lu<sup>2</sup>, Zijing Wu<sup>2</sup>, Zhiming Cai<sup>4,5</sup> and Lisha Mou<sup>2,3\*</sup>

<sup>1</sup>Imaging Department, Institute of Translational Medicine, Health Science Center, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China, <sup>2</sup>MetaLife Lab, Shenzhen Institute of Translational Medicine, Shenzhen, Guangdong, China, <sup>3</sup>Department of Endocrinology, Institute of Translational Medicine, Health Science Center, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China, <sup>4</sup>BGI Medical Group, Shenzhen, Guangdong, China, <sup>5</sup>Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China

**Background:** Islet transplantation is a promising treatment for type 1 diabetes that aims to restore insulin production and improve glucose control, but long-term graft survival remains a challenge due to immune rejection.

**Methods:** ScRNA-seq data from syngeneic and allogeneic islet transplantation grafts were obtained from GSE198865. Seurat was used for filtering and clustering, and UMAP was used for dimension reduction. Differentially expressed genes were analyzed between syngeneic and allogeneic islet transplantation grafts. Gene set variation analysis (GSVA) was performed on the HALLMARK gene sets from MSigDB. Monocle 2 was used to reconstruct differentiation trajectories, and cytokine signature enrichment analysis was used to compare cytokine responses between syngeneic and allogeneic grafts.

**Results:** Three distinct macrophage clusters (Mø-C1, Mø-C2, and Mø-C3) were identified, revealing complex interactions and regulatory mechanisms within macrophage populations. The significant activation of macrophages in allogeneic transplants was marked by the upregulation of allograft rejection-related genes and pathways involved in inflammatory and interferon responses. GSVA revealed eight pathways significantly upregulated in the Mø-C2 cluster. Trajectory analysis revealed that Mø-C3 serves as a common progenitor, branching into Mø-C1 and Mø-C2. Cytokine signature enrichment analysis revealed significant differences in cytokine responses, highlighting the distinct immunological environments created by syngeneic and allogeneic grafts.

**Conclusion:** This study significantly advances the understanding of macrophage roles within the context of islet transplantation by revealing the interactions

between immune pathways and cellular fate processes. The findings highlight potential therapeutic targets for enhancing graft survival and function, emphasizing the importance of understanding the immunological aspects of transplant acceptance and longevity.

#### KEYWORDS

type 1 diabetes (T1D), islet transplantation, macrophages, immune rejection, single-cell RNA sequencing (scRNA-seq), syngeneic transplantation, allogeneic transplantation, cytokine

#### 1 Introduction

Islet transplantation, a promising treatment for type 1 diabetes (T1D), aims to restore insulin production and achieve better glucose control (1). Although allogeneic islet transplantation has been approved and utilized in several countries for many years, the recent FDA approval of Lantidra in the United States marked a significant milestone in T1D treatment (2–4). According to a 20-year report of islet transplantation, significant progress has been made in improving graft survival and function, with advancements in immunosuppressive protocols and transplantation techniques contributing to better outcomes (5). Despite this progress, long-term graft survival and functionality remain challenging, primarily due to immune rejection (6, 7). Traditional approaches involve immunosuppressants, which have significant side effects, including increased infection and tumor risk (8–10).

The application of single-cell RNA sequencing (scRNA-seq) technology in islet transplantation is particularly novel and urgent due to its unparalleled ability to provide detailed insights into cellular heterogeneity and dynamic gene expression profiles at single-cell resolution. This technology allows us to dissect the complex immune microenvironment within transplanted islets, specifically focusing on macrophages, which play a pivotal role in graft acceptance and rejection. Previous methodologies, such as bulk RNA sequencing, lack the ability to identify distinct cellular subtypes and their specific functions within the graft microenvironment. In contrast, scRNA-seq enables the identification and characterization of diverse macrophage subsets and their roles in modulating immune responses.

The complexity of the immune microenvironment extends beyond the immediate challenges of immune rejection and immunosuppressant usage to include the elaborate interplay between transplanted islet cells and host immune cells, such as T cells (46), B cells, macrophages, dendritic cells, NK cells and neutrophils (11–13). Macrophages are critical in islet transplantation due to their dual role in promoting tissue repair and mediating immune responses (14). These versatile cells are involved in various processes, including phagocytosis, antigen presentation, and cytokine production, which influence graft survival and function. The ability of these cells to polarize into either proinflammatory (M1) or anti-inflammatory (M2) phenotypes significantly influences graft outcomes (15). Previous studies have highlighted the conflicting roles of macrophages in islet transplantation, with some reports indicating their contribution to graft rejection and others suggesting their involvement in immune tolerance. However, these studies were limited by their inability to precisely characterize macrophage subsets and their functional states within the transplant microenvironment.

Recent research underscores the therapeutic potential of macrophages due to their plasticity and diverse functions. Macrophage-based cell therapy can be engineered for tissue repair, immune modulation, and targeting specific diseases (14). Alpha-1 antitrypsin has been shown to suppress proinflammatory macrophage activity, improving islet graft survival (15). Polylysinebilirubin conjugates support islet viability and promote M2 macrophage polarization, aiding transplant acceptance (16). Islet transplantation can modulate macrophage activity to induce immune tolerance and promote angiogenesis, enhancing transplant success (17). Additionally, immunomodulatory injectable silk hydrogels maintain functional islets and promote M2 macrophage polarization, facilitating graft acceptance (18).

Our previous research identified three distinct macrophage subsets (Mø-C1, Mø-C2, and Mø-C3) through scRNA-seq, revealing their complex involvement in immune rejection and tolerance processes (19). Building on this foundational work, the current study presents a reanalysis of an existing scRNA-seq dataset from mouse transplantation models to characterize macrophage phenotypes associated with syngeneic and allogeneic islet grafts. The aim of this study was to further elucidate the mechanisms by which these macrophages contribute to transplantation outcomes. By comparing key pathways, we sought to uncover the specific roles of macrophage subsets in graft outcomes. This detailed profiling not only enhances our understanding of macrophage biology in islet transplantation but also identifies potential therapeutic targets to improve transplant success and longevity.

#### 2 Materials and methods

#### 2.1 Single-cell data analysis of islet grafts

ScRNA-seq data of syngeneic islet transplantation and allogeneic islet transplantation grafts were obtained from GSE198865 (19). Seurat (version 4.4.0) was used for filtering and subsequent clustering (20). Cells with RNA feature counts less than 200 or greater than 4500 and a mitochondrial content exceeding 15% were excluded as poor-quality cells. Genes not detected in at least 3 cells were removed from subsequent analysis. These thresholds were set to eliminate low-quality cells and potential doublets, ensuring the reliability of downstream analyses. The mitochondrial content threshold is based on the principle that high mitochondrial gene expression may indicate stressed or dying cells, which could bias the results.

Uniform manifold approximation and projection for dimension reduction (UMAP) (21) was performed using the Seurat R package with the first 75 principal components after performing principal component analysis (PCA) on the 2000 most highly expressed genes. Identification of significant clusters was performed using the FindClusters algorithm in the Seurat package with the resolution set to 0.6. Batch effect correction was performed using the "RunHarmony" function (22). Cell subtypes were annotated according to cell markers from the original study (19).

## 2.2 Differentially expressed genes (DEG) analyzed

For the analysis of DEGs, we used the Wilcoxon rank-sum test for comparisons between two groups. This nonparametric test is suitable for comparing two independent groups and is robust for single-cell RNA sequencing data. The analysis was further refined using the limma package in R (version 4.2.2), where genes were identified as differentially expressed based on two criteria: fold change > 0.25 and an adjusted *P* value < 0.05. Venn diagrams and heatmaps were generated to visualize the interactions between the DEGs and key pathway gene sets. Heatmaps were generated to visualize the results.

#### 2.3 Gene set variation analysis (GSVA)

Pathway analyses were predominantly performed on the HALLMARK gene sets described in the Molecular Signatures Database (MSigDB) and exported using the MSigDB package (version 7.5.1). We applied GSVA using standard settings, as implemented in the GSVA package (version 1.46.0) (23). Differences in pathway activity per cell according to GSVA among the different macrophage clusters. To correct for multiple comparisons, we employed the Benjamini-Hochberg method to control the false discovery rate (FDR). This correction is crucial for minimizing type I errors when conducting multiple statistical tests simultaneously.

#### 2.4 Analyzing the role of key gene sets in macrophages

To explore the roles of related gene sets in macrophages identified in GSVA, we conduct a specialized analysis of the expression patterns of these gene sets to uncover their potential role in transplant immune responses. Venn diagrams are used to display the intersection genes between each gene set and the DEGs in various macrophage subgroups from both syngeneic and allogeneic transplants.

## 2.5 Reconstruction of differentiation trajectories using Monocle 2

Using the R package Monocle 2 (version 2.8.0) (24), differentiation hierarchies within different clusters were reconstructed. Cell fate decisions and differentiation trajectories were reconstructed with the Monocle 2 package, which utilized reverse graph embedding based on a user-defined gene list to generate a pseudotime plot that could account for both branched and linear differentiation processes.

#### 2.6 Cytokine signature enrichment analysis

To assess the cytokine signatures of macrophage subsets (Mø-C1, Mø-C2, and Mø-C3) in syngeneic and allogeneic islet transplantation grafts, we utilized the Dictionary of Immune Responses to Cytokines at single-cell resolution. This approach was based on the transcriptional response data to individual cytokine stimulation collected by Cui et al. (25). We compared the cytokine signatures of macrophage subsets after allogeneic islet transplantation to those after syngeneic islet transplantation. Immune response enrichment analysis (IREA) (25) was subsequently conducted to calculate enrichment scores for each cytokine. This analysis identified the 86 cytokines with the enrichment for each macrophage subset.

#### 2.7 Statistical analysis

For the analysis of gene expression in the scRNA-seq data, all single-cell sequencing data statistical analyses were performed in the R Seurat package (version 4.4.0). Heatmaps were generated from the row-scaled expression values using the heatmap package in R (version 4.2.1). We established statistical significance at P < 0.05.

#### **3** Results

#### 3.1 The workflow of this study

The workflow of this study is illustrated in Figure 1. We began by acquiring single-cell datasets from GSE198865 covering both syngeneic and allogeneic islet grafts. Following stringent quality control, normalization, and initial dimensionality reduction, we used uniform manifold approximation and projection (UMAP) to distinguish cellular clusters from syngeneic and allogeneic islet grafts. ScRNA-seq analysis of macrophages revealed three distinct clusters (Mø-C1, Mø-C2, and Mø-C3) with their marker genes. We then conducted differential gene expression analysis across macrophage clusters (Mø-C1, Mø-C2, and Mø-C3) to identify differentially expressed genes (DEGs) between syngeneic and allogeneic grafts. Gene set variation analysis (GSVA) revealed pathway activity differences, with eight pathways upregulated in Mø-C2 macrophages. Intersection analysis identified key genes involved in pathways across Mø-C1, Mø-C2, and Mø-C3, as visualized through Venn diagrams and heatmaps. Trajectory analysis using Monocle 2 and cytokine signature enrichment analysis further elucidated macrophage dynamics and immune responses in islet transplantation.



#### 3.2 Analysis of single-cell datasets

In the foundational stage of our study, we accessed single-cell datasets encompassing both syngeneic and allogeneic islet grafts sourced from GSE198865 (19). After implementing rigorous quality control measures (Figures 2A, B), normalization processes, and initial dimensionality reduction steps, we utilized UMAP for dimension reduction. Cellular gene markers from the original dataset were used to categorize six primary cell types (Figure 2C): :lymphocytes(markers: Cd3e, Cd4 and Cd8), endothelial cells (markers: Pecam1, Egfl7 and Plvap), islet cells (markers: Ins1, Chga and Scg2), mesenchymal cells (markers: Col3a1, Col1a1 and Col1a2), myeloid cells (markers: Cd68, Gzma and Cd7), and acinar cells (markers: Amy2a, Ptf1a and Mist1). These major cell types were further partitioned into 11 subcell types (Figure 2D): B cells (markers: Cd19, Cd79a and Ms4a1), endothelial cells, islet cells, mesenchymal cells, CD4+ Th cells (markers: Cd4, Tnfsf8 and Lat), CD8+T cells (markers: Cd8a, Cd8b1 and Ms4a4b), regulatory T cells (Tregs, markers: Il2ra, Ctla4 and Cd2), macrophages (markers: Cd68, Csf1r and Pla2g7), natural killer cells (NK, markers: Gzma, Cd7 and Klrb1c), acinar cells and dendritic cells (DCs, markers: Clec9a, Xcr1 and Cd24a).

Meticulous scRNA-seq analysis of macrophage populations revealed three transcriptionally unique clusters, namely, Mø-C1, Mø-C2, and Mø-C3, providing deep insights into the heterogeneity and functional specialization of macrophage communities in the context of islet transplantation (Figure 2E). The marker genes of Mø-C1, Mø-C2, and Mø-C3 are shown in Figure 2F. The proportions of Mø-C1, Mø-C2, and Mø-C3 are shown in Figure 2G. The proportion of Mø-C1 cells was significantly greater in syngeneic grafts, whereas the proportion of Mø-C2 cells was considerably greater in allogeneic grafts. The proportion of Mø-C3 cells was similar in both the syngeneic and allogeneic grafts. This granular view of cellular landscapes sets the stage for a nuanced understanding of the immunological intricacies governing graft survival and acceptance.

# 3.3 Comparative analysis of DEGs in macrophages between syngeneic and allogeneic islet transplants

To investigate the molecular differences between macrophages from syngeneic versus allogeneic islet grafts, we conducted a thorough differential gene expression analysis. This approach enabled us to identify and characterize the DEGs across three distinct clusters of macrophages: Mø-C1 (Figure 2H, Supplementary Table 1), Mø-C2 (Figure 2I, Supplementary Table 2), and Mø-C3 (Figure 2J, Supplementary Table 3). By employing bioinformatics tools, we generated volcano plots to visually represent the DEGs between the syngeneic and allogeneic islet grafts within each macrophage subset. The analysis revealed significant differences in the expression of genes involved in critical pathways associated with graft acceptance, immune response modulation, and islet cell survival.

## 3.4 Key pathways upregulated in Mø-C2 macrophages during isletallograft transplantation

Pathway analyses primarily utilized HALLMARK gene sets from the Molecular Signatures Database (MSigDB), which are exported via the MSigDB package. GSVA scores per cell revealed pathway activity differences across macrophage clusters (Mø-C1, Mø-C2, and Mø-C3). Notably, eight pathways were significantly upregulated in Mø-C2 cells, underscoring their critical role in isletallograft transplantation. These pathways included DNA repair, MYC targets, G2M checkpoint, inflammatory response, E2F targets, allograft rejection, interferon alpha response, and interferon gamma response (Figure 3A). The number of DEGs within these pathways is detailed in Figure 3B.

#### 3.5 Signaling pathway dynamics in Mø-C1

Intersection analysis identified key genes involved in eight distinct pathways within the Mø-C1 macrophage cluster, as illustrated by the Venn diagram (Figure 4A). These pathways include DNA repair (including 2 genes), MYC targets (including 10 genes), G2M checkpoint (including 2 genes), inflammatory response (including 20 genes), E2F targets (including 1 gene), allograft rejection (including 17), interferon alpha response (including 9 genes), and interferon gamma response (including 25 genes). The heatmaps shows the up-regulated DEGs (Figure 4B) and down-regulated DEGs (Figure 4C) in allograft compared with syngeneic graft within these pathways. Detailed information on all DEGs in pathways related to Mø-C1 is provided in Supplementary Tables 4, 5. This analysis highlights the involvement of diverse genes in crucial pathways, shedding light on the multifaceted roles of Mø-C1 macrophages in islet grafts.

#### 3.6 Pathway analysis in Mø-C2

A Venn diagram (Figure 5A) was generated to identify genes significantly enriched in seven pathways within the Mø-C2 cluster. These pathways included DNA repair (including 2 genes), MYC targets (including 4 genes), G2M checkpoint (including 1 gene), inflammatory response (including 12 genes), allograft rejection (including 15 genes), interferon alpha response (including 7 genes), and interferon gamma response (including 24 genes). The heatmaps was generated to visualize the up-regulated DEGs (Figure 5B) and down-regulated DEGs (Figure 5C) in these pathways. Detailed information on all DEGs in pathways related to Mø-C2 is provided in Supplementary Tables 4, 5. This analysis underscores the significant activation of inflammatory and immune response pathways in Mø-C2 macrophages, particularly in the context of allograft rejection.



#### FIGURE 2

Single-cell RNA sequencing (scRNA-seq) insights into islet transplantation. (A) Quality control metrics for scRNA-seq of syngeneic and allogeneic islet grafts. (B) The number of detected genes showed no correlation with the percentage of mitochondrial content but was significantly correlated with sequencing depth. (C) Uniform manifold approximation and projection (UMAP) visualization highlights six predominant cell types within islet grafts, underscoring the diverse cellular landscape. (D) Further UMAP analysis revealed 11 subcell types, providing a detailed view of cellular diversity within the grafts. (E) Comparative UMAP plots of three macrophage clusters (Mø-C1, Mø-C2, and Mø-C3) in allogeneic (left panel) versus syngeneic (right panel) islet grafts reveal distinct cellular distributions. (F) Maker genes of three macrophage clusters. (G) The proportions of Mø-C1, Mø-C2, and Mø-C3. The number of Mø-C2 cells in allografts was significantly greater than that in syngeneic grafts. (H–J) The variance in gene expression between syngeneic and allogeneic grafts across macrophage clusters (Mø-C1, Mø-C2, and Mø-C3) is depicted, emphasizing the differential expression landscape. Mø, macrophage.



Gene set variation analysis (GSVA). (A) Pathway analyses primarily utilized HALLMARK gene sets from the Molecular Signatures Database (MSigDB), which were exported via the MSigDB package. GSVA scores per cell revealed pathway activity differences across macrophage clusters (Mø-C1, Mø-C2, and Mø-C3). The red box highlights eight pathways significantly upregulated in Mø-C2 cells, underscoring their critical role in islet-allograft transplantation. These pathways included DNA repair, MYC target, G2M checkpoint, inflammatory response, E2F target, allograft rejection, interferon alpha response, and interferon gamma response pathways. (B) The number of differentially expressed genes (DEGs) within pathways significantly upregulated in Mø-C2 macrophages. Mø, macrophage.

#### 3.7 Pathway insights for Mø-C3 macrophages

Key genes associated with five pathways in the Mø-C3 cluster were identified through intersection analysis, as shown in the Venn diagram (Figure 6A). These pathways included MYC targets (including 1 gene), inflammatory response genes (including 2 genes), allograft rejection genes (including 5 genes), interferon alpha response genes (including 5 genes), and interferon gamma response genes (including 7 genes). The heatmaps shows the upregulated DEGs (Figure 6B) and down-regulated DEGs (Figure 6C) within these pathways. Detailed information on all DEGs in pathways related to Mø-C3 cells is provided in Supplementary Tables 4, 5. This analysis revealed the significant roles of the interferon response and allograft rejection pathways in Mø-C3 macrophages, contributing to the understanding of their function in the immune response to transplantation.

#### 3.8 Macrophage transcriptional state bifurcation and cell fate of three clusters (Mø-C1, Mø-C2, and Mø-C3)

Trajectory manifold analysis of macrophages from islet grafts was conducted using the Monocle 2 algorithm, which identified distinct cellular trajectories or fates based on expression profiles (Figure 7A). The analysis revealed that macrophages primarily originate from the Mø-C3 cluster, which branches into the Mø-C1 and Mø-C2 clusters. Comparative trajectory analysis of macrophages from syngeneic and allogeneic grafts (Figure 7B) further elucidated these dynamics, showing that Mø-C3s serve as common progenitors for both transplant types.

The density plots (Figures 7C, D) illustrate the pseudotime projections of transcriptional changes for the three macrophage clusters (Mø-C1, Mø-C2, and Mø-C3). The proportion of Mø-C3



macrophage cluster, as shown in the Venn diagram. These pathways included DNA repair, MYC target, G2M checkpoint, inflammatory response, E2F target, allograft rejection, interferon alpha response, and interferon gamma response pathways. (**B**) Heatmap of up-regulated DEGs in allograft involved in these pathways. (**C**) Heatmap of down-regulated DEGs in allograft involved in these pathways. Mø, macrophage.

macrophages was relatively similar in both syngeneic and allogeneic grafts (Figure 2G), indicating that a stable progenitor state was unaffected by the type of graft. However, Mø-C1 macrophages were found in greater proportions in syngeneic grafts (Figure 2G),

suggesting that they play a role in promoting graft tolerance. Conversely, Mø-C2 macrophages were more prevalent in allogeneic grafts (Figure 2G), which is indicative of their involvement in inflammatory responses and graft rejection.



the down-regulated DEGs in allograft involved in these pathways. Mø, macrophage.

## 3.9 Cytokine signature enrichment in macrophages

To evaluate macrophages in islet grafts, we employed a comprehensive dictionary of immune responses to cytokines. Responses to 86 cytokines were analyzed by comparing syngeneic and allogeneic grafts (Figure 8A). The immune response enrichment analysis (IREA) cytokine enrichment plot (Figure 8B) displays the enrichment score (ES) for each cytokine response

across the three macrophage clusters (Mø-C1, Mø-C2, and Mø-C3) in syngeneic versus allogeneic grafts. The bar length represents the ES, while shading indicates the FDR-adjusted P value from a two-sided Wilcoxon rank-sum test, with darker shades reflecting greater statistical significance (red for allografts, blue for syngeneic grafts).

This evaluation is based on data collected by Cui et al. (25), where transcriptional responses to individual cytokine stimulation were measured. For Mø-C1s, the top 10 cytokines with the strongest



these pathways. Mø, macrophage

enrichment in allografts compared to syngeneic grafts were adiponectin, IL15, IFN $\alpha$ 1, IFN $\beta$ , IFN $\gamma$ , prolactin, IL7, IL11, IL18, and LIF (detailed results are provided in Supplementary Table 6). For Mø-C2s, the top 10 cytokines with the strongest enrichment in allografts were IFN $\gamma$ , IFN $\alpha$ 1, IFN $\beta$ , IL15, IL18, adiponectin, IL27, IL12, IL11, and IL36 $\alpha$  (detailed results are provided in Supplementary Table 7). For Mø-C3s, the top 10 cytokines with the strongest enrichment in allografts were IFN $\gamma$ , IFN $\alpha$ 1, IFN $\beta$ , IL15, IL18, adiponectin, IL2, IL12, IL36 $\alpha$ , and IFN $\kappa$  (detailed results are provided in Supplementary Table 8).

These analyses collectively offer a comprehensive view of the molecular underpinnings that define the macrophage-mediated response in syngeneic and allogeneic islet transplantation. By shedding light on the specific pathways and genes differentially expressed in various macrophage populations, this research underscores the complexity of the immune response to transplantation and points toward potential therapeutic targets for enhancing graft survival and function.

#### 4 Discussion

Single-cell RNA sequencing (scRNA-seq) technology has already found extensive applications in immunology (26) and

transplantation (27) research due to its ability to provide highresolution insights into cellular heterogeneity and the distinct functional states of individual cells. In this study, we leveraged single-cell RNA sequencing to thoroughly examine macrophage dynamics and molecular mechanisms in islet transplantation by comparing syngeneic and allogeneic grafts. By analyzing data from GSE198865 (19), we identified three distinct macrophage clusters (Mø-C1, Mø-C2, and Mø-C3) and explored their differential gene expression and pathway activities. Our detailed single-cell analysis revealed complex interactions and regulatory mechanisms within macrophage populations that were not previously captured by bulk RNA sequencing studies. This detailed view of cellular heterogeneity and functional specialization provides deeper insights into the molecular underpinnings of immune responses in transplantation, thereby the existing research.

Recent studies have demonstrated that macrophage heterogeneity and the distinct functional roles of various macrophage subpopulations are critical in shaping immune responses in different tissue contexts (28). For instance, research has shown that tissue-resident macrophages exhibit unique gene expression profiles and functional specializations depending on their tissue of origin and local microenvironment (29). Furthermore, the diversity of macrophage activation states, ranging from proinflammatory to anti-inflammatory and tissue



FIGURE 7

Macrophage transcriptional state bifurcation and cell fate of three clusters (Mø-C1, Mø-C2, and Mø-C3). (A) Multifold trajectories of macrophages from islet grafts analyzed using the Monocle 2 algorithm. Solid and dotted lines indicate distinct cellular trajectories or fates as determined by their expression profiles. (B) Comparative trajectory analysis of macrophages from syngeneic and allogeneic grafts using the Monocle 2 algorithm. (C, D) Density plots illustrating pseudotime projections of transcriptional changes for the three macrophage clusters (Mø-C1, Mø-C2, and Mø-C3). Mø, macrophage.

repair phenotypes, underscores the complexity of their roles in immune regulation (30).

By comparing our findings with those in the literature, we observe both the confirmation and expansion of previously reported results. The observed upregulation of allograft rejection, inflammatory response (31, 32), and interferon (33) signaling pathways in allogeneic transplants corroborates previous studies emphasizing the central role of these pathways in mediating inflammatory responses and immune rejection. However, our study extends these findings by providing a more nuanced understanding of the differences in macrophage polarization states between syngeneic and allogeneic transplants, highlighting a skew toward a more inflammatory phenotype in allogeneic settings. Our analysis revealed significant activation of macrophages in allogeneic transplants, marked by the upregulation of allograft rejection-related genes and pathways involved in inflammatory and interferon responses, supporting the hypothesis that immune rejection in allogeneic transplants is driven by the host's immune response to foreign antigens.

Gene set variation analysis (GSVA) is a nonparametric, unsupervised method that assesses pathway activity changes over a sample population in an expression dataset. GSVA transforms gene expression data from a gene-centric to a pathway-centric view, enabling the evaluation of pathway-level changes across samples (23). It has been widely utilized in immunological studies to elucidate the involvement of various signaling pathways in immune responses, disease mechanisms, and therapeutic interventions, providing insights into the functional context of gene expression alterations in immune cells (34). We used GSVA methods and identified eight pathways that were significantly upregulated in the Mø-C2 cluster, namely, DNA repair, MYC target, G2M checkpoint, inflammatory response, E2F target, allograft rejection, interferon alpha response, and interferon gamma response pathways. These pathways are crucial for understanding the immune response dynamics in islet transplantation and highlight potential therapeutic targets to modulate macrophage activity and improve graft outcomes.

Detailed intersection analyses and heatmaps of differentially expressed genes (DEGs) across the macrophage clusters provided insights into the polarization states of macrophages. These findings suggest a shift toward a proinflammatory phenotype in allogeneic transplants, which may contribute to graft rejection. This insight is crucial for developing targeted therapies that could reprogram macrophages to a more tolerogenic state.

Monocle 2, originally described by Qiu et al., utilizes a technique called reverse graph embedding to reconstruct the trajectories of single cells as they progress through different states (24). This method is particularly powerful for revealing the dynamic changes in cell fate decisions over time. Monocle 2 constructs a trajectory of single-cell transcriptomes by ordering cells along a pseudotime axis, which helps in understanding the progression and differentiation of cells in various biological processes.

Recent studies have demonstrated the application of Monocle 2 in various research contexts. For instance, Wang et al. (35) used Monocle 2 to create a single-cell transcriptome atlas of human



euploid and aneuploid blastocysts, providing insights into early human development and chromosomal abnormalities. Huang et al. (36) applied Monocle 2 to explore the molecular landscape of sepsis severity in infants, revealing that enhanced coagulation, innate immunity, and T-cell repression are key factors. Additionally, Su et al. (37) conducted a direct comparison of mass cytometry and single-cell RNA sequencing of human peripheral blood mononuclear cells using Monocle 2 to elucidate cellular heterogeneity and immune responses. Walzer et al. (38) employed Monocle 2 to study the transcriptional control of the Cryptosporidium life cycle, shedding light on the parasite's developmental stages and potential therapeutic targets. Furthermore, Wu et al. (39) integrated single-cell sequencing and bulk RNA-seq to identify and develop a prognostic signature related to colorectal cancer stem cells, utilizing Monocle 2 to trace the differentiation pathways of cancer stem cells. These applications highlight Monocle 2's versatility and effectiveness in tracing cell fate decisions and understanding complex biological processes, making it a valuable tool in both basic and translational research.

Trajectory analysis using Monocle 2 revealed distinct cellular trajectories and fate decisions within macrophage populations,

further elucidating the complexity of macrophage responses in islet grafts. The analysis showed that Mø-C3 serves as a common progenitor, branching into Mø-C1 and Mø-C2. Interestingly, the proportion of Mø-C3 cells was similar in both the syngeneic and allogeneic grafts, indicating that the baseline macrophage state was unaffected by the transplant type. In contrast, Mø-C1 cells were predominantly present in syngeneic grafts, while Mø-C2 cells were more abundant in allogeneic grafts. This suggests that Mø-C1 macrophages are more strongly associated with a tolerogenic environment, whereas Mø-C2 macrophages are linked to a more inflammatory response characteristic of graft rejection.

Our cytokine signature enrichment analysis revealed notable differences in cytokine responses between syngeneic and allogeneic grafts. For Mø-C1 macrophages, the top 10 cytokines with the strongest enrichment in allografts compared to syngeneic grafts included adiponectin, IL15, IFN $\alpha$ 1, IFN $\beta$ , IFN $\gamma$ , prolactin, IL7, IL11, IL18, and LIF. These cytokines are known to play diverse roles in immune modulation and inflammation. For example, IFN $\gamma$  (40, 41) and IFN $\beta$  (42) are critical for enhancing antigen presentation and promoting a Th1 immune response, which is often associated with graft rejection. Similarly, IL15 and IL18 (43) are potent

activators of NK cells and T cells, further contributing to the inflammatory milieu.

In Mø-C2 macrophages, the top 10 enriched cytokines in allografts were IFN $\gamma$ , IFN $\alpha$ 1, IFN $\beta$ , IL15, IL18, adiponectin, IL27, IL12, IL11, and IL36 $\alpha$ . The presence of IL27 (44) and IL12 (45) suggests their strong involvement in promoting Th1 and Th17 responses, which are crucial for initiating and sustaining immune responses against transplanted tissues. IL36 $\alpha$ , a member of the IL-1 cytokine family, is known for its role in amplifying inflammatory responses and has been implicated in autoimmune diseases, suggesting its potential involvement in graft rejection mechanisms.

For Mø-C3 macrophages, the top 10 enriched cytokines in allografts were IFN $\gamma$ , IFN $\alpha$ 1, IFN $\beta$ , IL15, IL18, adiponectin, IL2, IL12, IL36 $\alpha$ , and IFN $\kappa$ . IL2 is essential for T-cell proliferation and survival, indicating a supportive environment for effector T-cell responses in allogeneic grafts (45). The enrichment of IFN $\kappa$  (42), an interferon involved in antiviral responses, further highlights the complexity and multifaceted nature of the immune response in allogeneic grafts.

The enrichment of these cytokines in allografts underscores their critical roles in mediating immune responses and promoting inflammatory environments that are conducive to graft rejection. In contrast, syngeneic grafts, which are genetically identical to the host, do not provoke such robust inflammatory cytokine responses, allowing for better graft acceptance. Our findings align with previous studies showing that proinflammatory cytokines, such as IFN $\gamma$ , are upregulated in allogeneic transplants, contributing to graft rejection. Conversely, the role of anti-inflammatory cytokines such as IL-10 in supporting graft acceptance is well documented, highlighting their importance in creating a tolerogenic environment in syngeneic transplants.

The distinct cytokine profiles observed in our study highlight the importance of cytokine signaling pathways in shaping the immune landscape during transplantation. Targeting specific cytokines or their signaling pathways could offer new therapeutic strategies to balance immune activation and tolerance, thereby improving graft survival and function. Future research should focus on developing targeted therapies that modulate these cytokine responses to improve transplant outcomes.

While our study provides substantial insights, it is essential to acknowledge several limitations. Primarily, the reliance on animal models necessitates careful consideration when extrapolating findings to human clinical scenarios. Validation in human transplant samples is crucial to ensure clinical relevance. Additionally, single-cell RNA sequencing captures a snapshot of gene expression, which may not fully represent dynamic cellular processes.

Despite rigorous statistical methods, including the Wilcoxon rank-sum test and the limma package, there remains significant variability in gene expression profiles across different macrophage clusters and transplantation models. Differences in cell capture efficiency, sequencing depth, and batch effects can introduce biases, despite stringent quality control measures and batch effect correction. Future research should focus on corroborating these insights in human transplant samples and exploring the therapeutic potential of targeting identified pathways to modulate macrophage function and improve transplant efficacy. Exploring immune regulatory strategies that specifically target the proinflammatory macrophage response while avoiding broad immunosuppression represents a promising research direction. Finally, experimental validation of computational predictions, such as key pathway activation and cytokine expression, is essential to corroborate our results and translate them into clinical applications. Addressing these limitations in future studies will be critical for advancing our understanding of macrophage dynamics in islet transplantation and improving clinical outcomes.

In conclusion, our study significantly advances the knowledge of macrophage roles within the context of islet transplantation. By meticulously dissecting the interactions between immune pathways and cellular fate processes, we provide a detailed understanding of the immune response and identify potential targets for therapeutic intervention. These findings lay a foundation for innovative research pathways and therapeutic strategies aimed at improving transplantation therapies and achieving long-term success in treating type 1 diabetes. Our work underscores the necessity of further exploration to enhance transplant viability and highlights the importance of understanding the immunological aspects of transplant acceptance and longevity.

### Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

### Author contributions

LM: Conceptualization, Funding acquisition, Methodology, Writing – original draft, Writing – review & editing. SC: Formal analysis, Writing – review & editing. YL: Formal analysis, Visualization, Writing – review & editing. ZW: Formal analysis, Visualization, Writing – review & editing. ZC: Formal analysis, Funding acquisition, Writing – review & editing. ZP: Conceptualization, Funding acquisition, Methodology, Project administration, Supervision, Writing – review & editing.

### Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work is supported by the Shenzhen Science and Technology Program (JCYJ20230807115107015, GJHZ20240218114714027, JCYJ2022

0818102001003, and GCZX2015043017281705), Team-based Medical Science Research Program (2024YZZ04), Shenzhen High-level Hospital Construction Fund (2019), Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (ZXXM20190001/ZXXM20 200001/ZXXM20220001).

### Conflict of interest

Author ZC was employed by company BGI Medical Group.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

#### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

#### References

1. Bornstein SR, Ludwig B, Steenblock C. Progress in islet transplantation is more important than ever. *Nat Rev Endocrinol.* (2022) 18:389–90. doi: 10.1038/s41574-022-00689-0

 Harris E. FDA greenlights first cell therapy for adults with type 1 diabetes. JAMA. (2023) 330(5):402. doi: 10.1001/jama.2023.12542

3. Mullard A. FDA approves first cell therapy for type 1 diabetes. Nat Rev Drug Discovery. (2023) 22:611. doi: 10.1038/d41573-023-00113-w

4. FDA. FDA approves first cellular therapy to treat patients with type 1 diabetes (2023). Available online at: https://www.fda.gov/news-events/press-announcements/ fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes (Accessed February 5, 2024).

 Marfil-Garza BA, Imes S, Verhoeff K, Hefler J, Lam A, Dajani K, et al. Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada. *Lancet Diabetes Endocrinol.* (2022) 10:519–32. doi: 10.1016/S2213-8587(22) 00114-0

6. Chen Q-D, Liu L, Zhao X-H, Liang J-B, Li S-W. Challenges and opportunities in the islet transplantation microenvironment: a comprehensive summary of inflammatory cytokine, immune cells, and vascular endothelial cells. *Front Immunol.* (2023) 14:1293762. doi: 10.3389/fimmu.2023.1293762

7. Li Q, Lan P. Activation of immune signals during organ transplantation. Signal Transduct Target Ther. (2023) 8:110. doi: 10.1038/s41392-023-01377-9

8. Wang X, Brown NK, Wang B, Shariati K, Wang K, Fuchs S, et al. Local immunomodulatory strategies to prevent allo-rejection in transplantation of insulin-producing cells. Adv Sci. (2021) 8:2003708. doi: 10.1002/advs.202003708

9. Weir GC, Bonner-Weir S. Scientific and political impediments to successful islet transplantation. *Diabetes.* (1997) 46:1247–56. doi: 10.2337/diab.46.8.1247

10. Zahr E, Molano RD, Pileggi A, Ichii H, Jose SS, Bocca N, et al. Rapamycin impairs in *vivo* proliferation of islet beta-cells. *Transplantation*. (2007) 84:1576–83. doi: 10.1097/01.tp.0000296035.48728.28

11. Beilke JN, Kuhl NR, Kaer LV, Gill RG, Beilke JN, Kuhl NR, et al. NK cells promote islet allograft tolerance *via* a perforin-dependent mechanism. *Nat Med.* (2005) 11:1059–65. doi: 10.1038/nm1296

12. Yan L, Ye L, Chen Y, He S, Zhang C, Mao X, et al. The influence of microenvironment on survival of intraportal transplanted islets. *Front Immunol.* (2022) 13:849580. doi: 10.3389/fimmu.2022.849580

#### Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1407118/ full#supplementary-material

**SUPPLEMENTARY TABLE 1** Total DEGs in Mø-C1.

**SUPPLEMENTARY TABLE 2** Total DEGs in Mø-C2.

**SUPPLEMENTARY TABLE 3** Total DEGs in Mø-C3

**SUPPLEMENTARY TABLE 4** Up-regulated DEGs in allograft in related pathways.

#### SUPPLEMENTARY TABLE 5

Down-regulated DEGs in allograft in related pathways

**SUPPLEMENTARY TABLE 6** Cytokine Signature Enrichment in Mø-C1.

**SUPPLEMENTARY TABLE 7** Cytokine Signature Enrichment in Mø-C2.

SUPPLEMENTARY TABLE 8 Cytokine Signature Enrichment in Mø-C3.

13. Li X, Meng Q, Zhang L. The fate of allogeneic pancreatic islets following intraportal transplantation: challenges and solutions. *J Immunol Res.* (2018) 2018:2424586. doi: 10.1155/2018/2424586

14. Na YR, Kim SW, Seok SH. A new era of macrophage-based cell therapy. *Exp Mol Med.* (2023) 55:1945–54. doi: 10.1038/s12276-023-01068-z

15. Gou W, Wang J, Song L, Kim D-S, Cui W, Strange C, et al. Alpha-1 antitrypsin suppresses macrophage activation and promotes islet graft survival after intrahepatic islet transplantation. *Am J Transplant.* (2021) 21:1713–24. doi: 10.1111/ajt.16342

16. Zhao Y-Z, Huang Z-W, Zhai Y-Y, Shi Y, Du C-C, Zhai J, et al. Polylysinebilirubin conjugates maintain functional islets and promote M2 macrophage polarization. *Acta Biomater.* (2021) 122:172–85. doi: 10.1016/j.actbio.2020.12.047

17. Li Y, Ding X, Tian X, Zheng J, Ding C, Li X, et al. Islet transplantation modulates macrophage to induce immune tolerance and angiogenesis of islet tissue in type I diabetes mice model. *Aging (Albany NY)*. (2020) 12:24023–32. doi: 10.18632/aging.104085

18. Kumar M, Gupta P, Bhattacharjee S, Nandi SK, Mandal BB. Immunomodulatory injectable silk hydrogels maintaining functional islets and promoting antiinflammatory M2 macrophage polarization. *Biomaterials*. (2018) 187:1–17. doi: 10.1016/j.biomaterials.2018.09.037

19. Chen P, Yao F, Lu Y, Peng Y, Zhu S, Deng J, et al. Single-cell landscape of mouse islet allograft and syngeneic graft. *Front Immunol.* (2022) 13:853349. doi: 10.3389/fimmu.2022.853349

20. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. *Cell.* (2021) 184:3573-3587.e29. doi: 10.1016/j.cell.2021.04.048

21. McInnes L, Healy J, Saul N, Großberger L. UMAP: Uniform manifold approximation and projection. JOSS. (2018) 3:861. doi: 10.21105/joss.00861

22. Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat Methods*. (2019) 16:1289–96. doi: 10.1038/s41592-019-0619-0

23. Hänzelmann S, Castelo R, Guinney J, Hänzelmann S, Castelo R, Guinney J, et al. GSVA: gene set variation analysis for microarray and RNA-Seq data. *BMC Bioinf.* (2013) 14:7. doi: 10.1186/1471-2105-14-7

24. Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA, et al. Reversed graph embedding resolves complex single-cell trajectories. *Nat Methods*. (2017) 14:979–82. doi: 10.1038/nmeth.4402

25. Cui A, Huang T, Li S, Ma A, Pérez JL, Sander C, et al. Dictionary of immune responses to cytokines at single-cell resolution. *Nature*. (2024) 625:377-84. doi: 10.1038/s41586-023-06816-9

26. Irac SE, Soon MSF, Borcherding N, Tuong ZK, Irac SE, Soon MSF, et al. Singlecell immune repertoire analysis. *Nat Methods*. (2024) 21:777–92. doi: 10.1038/s41592-024-02243-4

27. Wang Y, Wang J-Y, Schnieke A, Fischer K, Wang Y, Wang J-Y, et al. Advances in single-cell sequencing: insights from organ transplantation. *Military Med Res.* (2021) 8:45. doi: 10.1186/s40779-021-00336-1

28. Mass E, Nimmerjahn F, Kierdorf K, Schlitzer A, Mass E, Nimmerjahn F, et al. Tissue-specific macrophages: how they develop and choreograph tissue biology. *Nat Rev Immunol.* (2023) 23:563–79. doi: 10.1038/s41577-023-00848-y

29. Kloc M, Kubiak JZ. Monocyte and macrophage function diversity. *IJMS*. (2022) 23:12404. doi: 10.3390/ijms232012404

30. Lendeckel U, Venz S, Wolke C, Lendeckel U, Venz S, Wolke C. Macrophages: shapes and functions. *ChemTexts*. (2022) 8:12. doi: 10.1007/s40828-022-00163-4

31. Chung WY, Pollard CA, Kumar R, Drogemuller CJ, Naziruddin B, Stover C, et al. A comparison of the inflammatory response following autologous compared with allogenic islet cell transplantation. *Ann Transl Med.* (2021) 9:98–8. doi: 10.21037/atm-20-3519

32. Ravindranath MH, El Hilali F, Filippone EJ. The impact of inflammation on the immune responses to transplantation: tolerance or rejection? *Front Immunol.* (2021) 12:667834. doi: 10.3389/fimmu.2021.667834

33. Kloc M, Ghobrial RM. Chronic allograft rejection: A significant hurdle to transplant success. *Burns Trauma*. (2014) 2:3–10. doi: 10.4103/2321-3868.121646

34. Chen Y-P, Yin J-H, Li W-F, Li H-J, Chen D-P, Zhang C-J, et al. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. *Cell Res.* (2020) 30:1024–42. doi: 10.1038/s41422-020-0374-x

35. Wang S, Leng L, Wang Q, Gu Y, Li J, An Y, et al. A single-cell transcriptome atlas of human euploid and aneuploid blastocysts. *Front Immunol.* (2024) 15:1468–81. doi: 10.1038/s41588-024-01788-6

36. Huang SSY, Toufiq M, Eghtesady P, Van Panhuys N, Garand M, Huang SSY, et al. The molecular landscape of sepsis severity in infants: enhanced coagulation, innate immunity, and T cell repression. *Front Immunol.* (2024) 15:1281111. doi: 10.3389/fimmu.2024.1281111

37. Su EY, Fread K, Goggin S, Zunder ER, Cahan P. Direct comparison of mass cytometry and single-cell RNA sequencing of human peripheral blood mononuclear cells. *Sci Data*. (2024) 11:559. doi: 10.1038/s41597-024-03399-6

38. Walzer KA, Tandel J, Byerly JH, Daniels AM, Gullicksrud JA, Whelan EC, et al. Transcriptional control of the Cryptosporidium life cycle. *Nature*. (2024) 630:174–80. doi: 10.1038/s41586-024-07466-1

39. Wu J, Li W, Su J, Zheng J, Liang Y, Lin J, et al. Integration of single-cell sequencing and bulk RNA-seq to identify and develop a prognostic signature related to colorectal cancer stem cells. *Sci Rep.* (2024) 14:12270. doi: 10.1038/s41598-024-62913-3

40. Merli P, Caruana I, De Vito R, Strocchio L, Weber G, Bufalo FD, et al. Role of interferon- $\gamma$  in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation. *Haematologica*. (2019) 104:2314–23. doi: 10.3324/haematol.2019.216101

41. Halawi A, El Kurdi AB, Vernon KA, Solhjou Z, Choi JY, Saad AJ, et al. Uncovering a novel role of focal adhesion and interferon-gamma in cellular rejection of kidney allografts at single cell resolution. *Front Immunol.* (2023) 14:1139358. doi: 10.3389/fimmu.2023.1139358

42. Fueyo-González F, McGinty M, Ningoo M, Anderson L, Cantarelli C, Angeletti A, et al. Interferon- $\beta$  acts directly on T cells to prolong allograft survival by enhancing regulatory T cell induction through Foxp3 acetylation. *Immunity.* (2022) 55:459–474.e7. doi: 10.1016/j.immuni.2022.01.011

43. Boieri M, Ulvmoen A, Sudworth A, Lendrem C, Collin M, Dickinson AM, et al. IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development. *vivo OncoImmunol.* (2017) 6:e1274478. doi: 10.1080/2162402X.2016.1274478

44. Wu S, Ma R, Zhong Y, Chen Z, Zhou H, Zhou M, et al. Deficiency of IL-27 signaling exacerbates experimental autoimmune uveitis with elevated uveitogenic th1 and th17 responses. *IJMS*. (2021) 22:7517. doi: 10.3390/ijms22147517

45. Ashour D, Arampatzi P, Pavlovic V, Förstner KU, Kaisho T, Beilhack A, et al. IL-12 from endogenous cDC1, and not vaccine DC, is required for Th1 induction. *JCI Insight*. (2020) 5:e135143. doi: 10.1172/jci.insight.135143

46. Zhou H, Pu Z, Lu Y, Zheng P, Yu H, Mou L. Elucidating T cell dynamics and molecular mechanisms in syngeneic and allogeneic islet transplantation through single-cell RNA sequencing. *Front Immunol.* (2024) 15:1429205. doi: 10.3389/fimmu.2024.1429205